Issue 25

Is the Term “CDMO” Outdated and in Need of Replacing?

Why not sign up for our future email newsletters? Sign up here.

Included in this issue:

LEAD STORY

CRO, CMO, CDMO: What's Next?

The term CDMO has become ubiquitous in the pharmaceutical industry over the past decade, but is it merely a buzzword or does it represent a genuine paradigm shift?

Read more here.

FEATURED STORIES

Pharmaceutical Industry Deals Hit Decade-Low in 2024: A Shift Towards Smaller Acquisitions

Read more here.

Adragos Pharma Expands Sterile Manufacturing Prowess with Swiss Acquisition 

Read more here.

Hovione Expands Cork Facility, Boosts Spray Drying Capacity 

Read more here.

Schreiner MediPharm's Innovative Label Enhances WuXi XDC's Clinical Trials

Read more here.

Roche Acquires Poseida Therapeutics, Boosting Cell Therapy Portfolio

Read more here.

Bristol Myers Squibb Implements Layoffs in New Jersey Amid Cost-Cutting Measures 

Read more here.

Dyadic Secures Gates Foundation Grant to Develop Accessible Antibodies for RSV and Malaria 

Read more here.

Celltrion to Break Ground on CDMO Plant in 2025  

Read more here.

KPMG Life Sciences CEO Outlook Report

Read more here.

Read more here.

BioDuro-Sundia Appoints Alan Findlater as New Chief Commercial Officer

Read more here.